-
Views
-
Cite
Cite
Jaqueline Munhoz, Gabriela Peron, Amanda Pires Bonfanti, Janine Oliveira, Thomaz A A da Rocha‐e‐Silva, Rafael Sutti, Rodolfo Thomé, André Luís Bombeiro, Natalia Barreto, Ghanbar Mahmoodi Chalbatani, Elahe Gharagouzloo, João Luiz Vitorino-Araujo, Liana Verinaud, Catarina Rapôso, Components from spider venom activate macrophages against glioblastoma cells: new potential adjuvants for anticancer immunotherapy, The Journal of Biochemistry, Volume 170, Issue 1, July 2021, Pages 51–68, https://doi.org/10.1093/jb/mvab020
- Share Icon Share
Abstract
Immunomodulation has been considered an important approach in the treatment of malignant tumours. However, the modulation of innate immune cells remains an underexplored tool. Studies from our group demonstrated that the Phoneutria nigriventer spider venom (PnV) administration increased the infiltration of macrophage in glioblastoma, in addition to decreasing the tumour size in a preclinical model. The hypothesis that PnV would be modulating the innate immune system led us to the main objective of the present study: to elucidate the effects of PnV and its purified fractions on cultured macrophages. Results showed that PnV and the three fractions activated macrophages differentiated from bone marrow precursors. Further purification generated 23 subfractions named low weight (LW-1 to LW-12) and high weight (HW-1 to HW-11). LW-9 presented the best immunomodulatory effect. Treated cells were more phagocytic, migrated more, showed an activated morphological profile and induced an increased cytotoxic effect of macrophages on tumour cells. However, while M1-controls (LPS) increased IL-10, TNF-alpha and IL-6 release, PnV, fractions and subfractions did not alter any cytokine, with the exception of LW-9 that stimulated IL-10 production. These findings suggest that molecules present in LW-9 have the potential to be used as immunoadjuvants in the treatment of cancer.

Phoneutria nigriventer spider venom (PnV) modulates bone marrow-derived macrophages in a activate profile with antitumoural activity in glioblastoma cells. Furthermore, the screening showed that LW-9 presented the best immunomodulatory effect. Treated cells were more phagocytic, migrated more, showed an activated morphological profile and induced an increased cytotoxic effect of macrophages on tumour cells and did not alter any cytokine, with the exception of LW-9 that stimulated IL-10 production. These findings suggest that molecules present in LW-9 have the potential to be used as immunoadjuvants in the treatment of cancer.